• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 4 (2), 2008
  3. 149-152
  • Issues
    Online First Current Issue All Issues

International Journal of Pharmacology

Year: 2008 | Volume: 4 | Issue: 2 | Page No.: 149-152
DOI: 10.3923/ijp.2008.149.152

Facebook Twitter Reddit Linkedin E-mail
ASCI
Research Article

Pharmacokinetic Analysis of Warfarin in Iranian Warfarin Sensitive Patients

S. Sadrai
Faculty of Pharmacy, Tehran University/Medical Sciences, Tehran, Iran

P. Ghadam
Department of Biochemistry, Faculty of Sciences, Alzahra University, Tehran, Iran

R. Sharifian
Department of Hematology, Tehran University/Medical Sciences, Imam Hospital, Tehran, Iran

E. Nematipour
Department of Cardiology, Tehran University/Medical Sciences, Imam Hospital, Tehran, Iran

Z. Kianmehr
Department of Biochemistry, Faculty of Sciences, Alzahra University, Tehran, Iran

Sh. Shahriari
Department of Biochemistry, Faculty of Sciences, Alzahra University, Tehran, Iran

In this study, we investigated pharmacokinetic of warfarin in sensitive and control patients by HPLC. The analysis performed by HPLC consisted of a column (Perfectsil Target, 5 μm, 125x4.0 mm) and an isocratic mobile phase of methanol: acetonitrile: phosphate buffer (pH: 3.5) (7:55:38, v/v), flow rate: 1 mL min-1 and UV detection at 270 nm. The assay was linear in warfarin concentration ranges of 0.1-10 μg mL-1 (r2 = 0.9975) and with Relative Standard Deviation (RSD) of <8% for inter-day and <6% for intra-day. The mean warfarin blood concentration of 54 patients was 1.2 ± 0.6 μg mL-1.
PDF Fulltext XML References Citation

How to cite this article

S. Sadrai, P. Ghadam, R. Sharifian, E. Nematipour, Z. Kianmehr and Sh. Shahriari, 2008. Pharmacokinetic Analysis of Warfarin in Iranian Warfarin Sensitive Patients. International Journal of Pharmacology, 4: 149-152.

DOI: 10.3923/ijp.2008.149.152

URL: https://scialert.net/abstract/?doi=ijp.2008.149.152

Related Articles

VKORC1 Gene Analysis of Some Iranian Sensitive Patients to Warfarin

Leave a Comment


Your email address will not be published. Required fields are marked *

Article Trend



Total views 3073

References


  1. Andalibi, P., H. Farsam, M. Amanlou and M. Gharouni, 1998. Determination of dosage requirements of warfarin in Iranian patients using HPLC technique. J. Clin. Pharma. Ther., 23: 199-204.
    PubMed

  2. Ansell, J., J. Hirsh, J. Dalen, H. Bussey and D. Anderson et al., 2001. Managing oral anticoagulant therapy. Chest, 119: 22s-38s.
    PubMedDirect Link

  3. Cannegieter, S.C., F.R. Rosendaal, A.R. Wintzen, F.J.M. van der Meer, J.P. Vandenbroucke and E. Briet, 1995. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med., 333: 7-11.
    Direct Link

  4. Depr´e, M.A., M. Van Hecken, I. Oeyen, T. De Lepeleire and P. Laethem et al., 2005. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur. J. Clin. Pharmacol., 61: 341-346.
    CrossRefPubMedDirect Link

  5. Hirsh, J., J.E. Dalen, D.R. Anderson, L. Poller and H. Bussey et al., 1998. Oral anticoagulants: Mechanisms of action, clinical effectiveness and optimal therapeutic range. Chest, 114: 445S-468S.
    PubMed

  6. Hirsh, J., J.E. Dalen, D.R. Anderson, L. Poller and H. Bussey et al., 2001. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. Chest, 119: 8S-21S.

  7. Levine, M.N., G. Raskob, S. Landefeld and C. Kearon, 2001. Hemorrhagic complications of anticoagulant treatment. Chest, 119: 108S-121S.
    PubMedDirect Link

  8. Linder, M.W., 2001. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin. Clin. Chim. Acta, 308: 9-15.
    CrossRefPubMedDirect Link

  9. Lombardi, R., V. Chantarangkul, M. Cattaneo and A. Tripodi, 2003. Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio. J. Thrombosis Res., 111: 281-284.
    CrossRef

  10. Modi, N.B., S. Kell, M. Simon and R. Vargas, 2005. Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium. J. Clin. Pharmacol., 45: 919-926.
    PubMedDirect Link

  11. Sconce, E.A., T.I. Khan, H.A. Wynne, P. Avery and L. Monkhouse et al., 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood, 106: 2329-2333.
    CrossRefPubMedDirect Link

  12. Sun, S., M. Wang, L. Su, J. Li, H. Li and D. Gu, 2006. Study on warfarin plasma concentration and its correlation with international normalized ratio. J. Pharm. Biomed. Anal., 42: 218-222.
    CrossRefPubMedDirect Link

  13. Takahashi, H., G.R. Wilkinson, Y. Caraco, M. Muszkat and R.B. Kim et al., 2003. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. J. Clin. Pharmacol. Ther., 73: 253-263.
    CrossRefPubMedDirect Link

  14. Taube, J., D. Halsall and T. Baglin, 2000. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 96: 1816-1819.
    PubMedDirect Link

  15. Van der Meer, F.J.M., F.R. Rosendaal, J.P. Vandenbroucke and E. Briet, 1993. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch. Int. Med., 153: 1557-1562.
    Direct Link

  16. Zhao, F., C. Loke, S. Rankin and J. Guo, 2004. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 76: 210-219.
    CrossRefPubMedDirect Link

Keywords


  • warfarin sensitivity
  • pharmacokinetics
  • warfarin
  • HPLC

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved